Back to reports
0
0

Israel Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape

Pages: 192 Published: June 16, 2022 Report Code: GDHC0071CHR

Add to Wishlist
Select Item

Israel pharmaceutical market size was $2.4 billion in 2018. The market value is expected to grow further by 2027. Key drivers of Israel’s pharmaceutical industry are a strong network of academic and research institutes, R&D facilities, and developed medical facilities.

Israel Healthcare (Pharma and Medical Devices) Market Analysis

For more pharmaceutical insights, download a free report sample

Israel medical devices market size was $1.6 billion in 2021. The market is expected to grow at a CAGR of more than 2% during the period 2022-2028. In Israel’s life science industry, medical devices is a leading segment. The top import medical devices are surgical instruments and other medical electronics, lab reagents, diagnostic equipment, and catheters.

Israel Healthcare (Pharma and Medical Devices) Market Analysis

For more medical devices insights, download a free report sample

What are the market dynamics in the Israel pharmaceutical market?

Israel’s supply channel consists of the drug manufacturer or importer, the drugstore, the pharmacy, and consumers. As per section 12B of the Pharmacists Ordinance (New Version) 1981, drugs can only be sold in Israel through a pharmacy, drug store, or a recognized university. Before the distribution of medicine, the manufacturer or importer is obliged to list the drug in the Register of Preparations by applying it to the MOH.  Drug stores are the wholesaler suppliers of medicines that supply drugs to the authorized pharmacies and recognized medical institutes. It is necessary for each participant of the supply channel to procure drugs only from an authorized unit of Israel.

What are the key segments in the Israel pharmaceutical market?

The key segments in the pharmaceutical market are generics, biologics, biosimilars, and over-the-counter (OTC).

On April 25, 2022, Israel-based Sol-Gel Technologies, a dermatological-preparation company, announced the FDA approval of Epsolay. Epsolay is a cream formulation used for the treatment of rosacea inflammatory lesions in adults.

Who are the key players in the Israel pharmaceutical market?

The key players in the Israel pharmaceutical market are Sanofi, Bayer AG (Bayer), Merck & Co. (Merck), GlaxoSmithKline (GSK), Teva Pharmaceutical Industries Ltd (Teva), and Kamada Pharmaceuticals (Kamada).

Sanofi

Sanofi is a healthcare company that researches, develops, manufactures, and markets a wide range of medicines and vaccines. It has operations across Europe, the Americas, Asia-Pacific, Africa, and the Middle East. Sanofi is headquartered in Paris, France. In Israel, it operates from Netanya.

Bayer AG (Bayer)

Bayer AG (Bayer) discovers, develops, manufactures, and commercializes products for human healthcare and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology, and other indications. Bayer is headquartered in Leverkusen, Germany. In Israel, it operates from Hod Hasharon.

Merck & Co. (Merck)

Merck & Co. (Merck) is a global healthcare company that focuses on the R&D of innovative products for the improvement of human and animal health. Merck is known as MSD outside the US and Canada. It is headquartered in New Jersey, US. In Israel, it operates from Hod Hasharon.

GlaxoSmithKline (GSK)

GlaxoSmithKline (GSK) is a healthcare company that focuses on the development, manufacture, and commercialization of pharmaceuticals, vaccines, and consumer healthcare products. It offers drugs for the treatment of respiratory diseases, cancer, cardiovascular diseases, human immunodeficiency virus (HIV), infectious diseases, immuno-inflammation, and rare diseases. It is headquartered in Brentford, London. In Israel, its office is in Petach Tikva.

What are the key segments in the Israel medical devices market?

The key segments in the Israel medical devices market are Cardiovascular Devices, Hospital Supplies, Orthopedic Devices, Neurology Devices, General Surgery Devices. Cardiovascular devices has the highest revenue.

Who are the key players in the Israel medical devices market?

The key players in the Israel medical devices market are Abbott, GE Healthcare, Zimmer Biomet Holdings Inc (Zimmer Biomet), Coloplast A/S (Coloplast), SHL TeleMedicine Ltd (SHL), and BioView Ltd (BioView).

Abbott

Abbott is a diversified health product company that manufactures and markets drugs, diagnostics, branded generics, vascular products, and nutritional products. The company’s products comprise specialized medicines, medical diagnostic instruments and tests, minimally invasive surgical devices, and products for veterinary care. Abbott is headquartered in Illinois, US, with its Israel office located in Tel Aviv.

GE Healthcare

GE Healthcare is a business unit of General Electric Company. It manufactures and sells medical imaging devices for diagnosis and other medical devices. GE Healthcare is headquartered in Chicago, Illinois, US. In Israel, it operates from Haifa. is a business unit of General Electric Company. It manufactures and sells medical imaging devices for diagnosis and other medical devices. GE Healthcare is headquartered in Chicago, Illinois, US. In Israel, it operates from Haifa.

Zimmer Biomet Holdings Inc (Zimmer Biomet)

Zimmer Biomet Holdings Inc (Zimmer Biomet) is a medical device company focused on musculoskeletal healthcare. The company designs, manufactures, and markets orthopedic reconstructive products, sports medicine, biologics, extremities and trauma products, spine products, craniomaxillofacial and thoracic products, office-based technologies, dental implants, and related surgical products. Zimmer Biomet is headquartered in Warsaw, Indiana, US. Zimmer Biomet’s office in Israel is in Ramat Gan, Tel Aviv.

Market report overview of pharmaceutical market in Israel

Market size 2018 $2.4 billion
Key segments Generics, Biologics, Biosimilars, and Over-The-Counter (OTC)
Major players Sanofi, Bayer AG (Bayer), Merck & Co. (Merck), GlaxoSmithKline (GSK), Teva Pharmaceutical Industries Ltd (Teva), and Kamada Pharmaceuticals (Kamada)

Market report overview of medical devices market in Israel

Market size 2021 $1.6 billion
CAGR% (2022-2028) >2%
Key segments Cardiovascular Devices, Hospital Supplies, Orthopedic Devices, Neurology Devices, General Surgery Devices
Major players Abbott, GE Healthcare, Zimmer Biomet Holdings Inc (Zimmer Biomet), Coloplast A/S (Coloplast), SHL TeleMedicine Ltd (SHL), and BioView Ltd (BioView)

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Israel, and includes:

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers.
  • Profiles and SWOT analyses of the major players in the pharmaceutical market: Sanofi, Bayer, Merck, GlaxoSmithKline (GSK), Teva Pharmaceuticals, and Kamada.
  • Profiles and SWOT analyses of the major players in the medical device market: Abbott, GE Healthcare, Bioview, Zimmer Biomet, Coloplast, and SHL Telemedicine.
  • An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in healthcare market, HealthTech landscape, reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices.
  • Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure and healthcare expenditure.
  • An overview of the opportunities for and challenges to growth in the Israeli healthcare market.

Reasons to Buy

  • This report will enhance your decision-making capability by allowing you to:

  • Develop business strategies by understanding the trends shaping and driving the Israeli healthcare market

  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact the Israeli healthcare market in the future

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance

  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership

Table of Contents

1. Table of Contents

1.1 List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights: Facts About the Israeli Healthcare Market

2.3 Key Highlights: Healthcare Startups in Israel

2.4 Key Events: Israeli Healthcare Timeline, 2016–22

2.5 Key Events: Israeli Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2020–22

2.7 Key Events: Mergers and Acquisitions

2.8 Country Profile, Israel, 2021

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, Israel

3.5 Pharmaceutical Market – Medical Tourism, Israel

3.6 Pharmaceutical Market – Market Segments

3.7 Pharmaceutical Market – Market Segments, Generics, Israel

3.8 Pharmaceutical Market – Market Segments, Biologics and Biosimilars, Israel

3.9 Pharmaceutical Market – Market Segment, Over-the-Counter Medicines, Israel

3.10 COVID-19 Epidemiology, Israel

3.11 COVID-19 Impact and Developments in the Healthcare Market, Israel

3.12 COVID-19 Clinical Trials Landscape, Israel

3.13 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Devices Market – Major Segments

4.3 Medical Devices Market – Cardiovascular Devices Market

4.4 Medical Devices Market – Hospital Supplies Market

4.5 Medical Devices Market – Orthopedic Devices Market

4.6 Medical Devices Market – Neurology Devices Market

4.7 Medical Devices Market – General Surgery Devices Market

4.8 Medical Devices Market – Diagnostic Market

4.9 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, Israel, 2021–22

6.2 Deal Analysis: Medical Device Market, Israel, 2021–22

7. Healthtech Landscape

7.1 Healthtech Landscape, Israel

7.2 Healthtech Deals Landscape, Israel

7.3 Key Healthtech Deals, Israel

7.4 Adoption of Technology in Healthcare, Israel

7.5 Digital Statistics, Israel

7.6 Digital Regulations, Israel

7.7 Healthtech Landscape: Benefits and Risks, Israel

8. Market Access

8.1 Overview of Healthcare System, Israel

8.2 Reimbursement Landscape, Israel

8.3 Overview of Insurance Providers, Public Insurance, Israel

8.4 Overview of Insurance Providers, Private Insurance, Israel

8.5 Healthcare Spending and Prescription Drug Price Trend, Israel

8.6 Pricing Policies, Israel

8.7 Market Access: Key Events Timeline, Israel, 2010–22

8.8 Regulatory Landscape, Israel

8.8.1 Marketing Authorization for Pharmaceutical Products, Israel

8.8.2 Marketing Authorization for Medical Devices, Israel

8.8.3 Intellectual Property Rights, Patent, Israel

8.8.4 Intellectual Property Rights, Patent Prosecution Highway, Israel

8.8.5 Intellectual Property Rights, Trademark, Israel

8.8.6 Clinical Trial Regulation Process, Israel

8.8.7 Pharmaceutical Clinical Trials Landscape, Israel

8.8.8 Medical Device Clinical Trials Landscape, Israel

8.8.9 Clinical Trials Landscape, Israel

8.8.10 Pharmaceutical Import and Export, Israel

8.8.11 Pharmaceutical Advertising Regulations, Israel

8.8.12 Labeling and Packaging Regulations, Israel

9. Country Healthcare Landscape

9.1 Israeli Healthcare Policy Highlights

9.2 Healthcare Facilities, Israel

9.3 Healthcare Resources, Israel

9.4 Life Expectancy and Immunization Rate, Israel

9.5 Environmental Health, Israel

9.6 Healthcare Personnel, Israel

9.7 Disease Burden, Israel

9.8 Healthcare Expenditure, Israel

10 Trade Associations, Israel

11 Trade Fairs, Israel

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

List of Tables

Table 1: COVID-19 indicators (number of cases), Global and Israel, 2022

Table 2: COVID-19-related travel restrictions, Israel, 2020–22

Table 3: Available COVID-19 IVD products, Israel, 2021–22

Table 4: Pipeline COVID-19 IVD products, Israel, 2021-22

Table 5: Approved vaccines, Israel, 2022

Table 6: COVID-19 vaccine trials, Israel, 2022

Table 7: Medical devices market, major segments ($M), Israel, 2021

Table 8: Cardiovascular devices market, revenue ($M) and market share (%) of major companies, Israel, 2021

Table 9: Hospital supplies market, revenue ($M) and market share (%) of major companies, Israel, 2021

Table 10: Orthopedic devices market, revenue ($M) and market share (%) of major companies, Israel, 2021

Table 11: Neurology devices market, revenue ($M) and market share (%) of major companies, Israel, 2021

Table 12: General surgery devices market, revenue ($M) and market share (%) of major companies, Israel, 2021

Table 13: Health insurance contributions, Israel, 2022

Table 14: Comparison between health plans, group commercial, and individual commercial, Israel, 2022

Table 15: Pharmacist margin, Israel, 2022

Table 16: Patent approval fees, Israel, 2022

Table 17: Trademark fees, Israel, 2022

Table 18: CCS, Israel, 2022

Table 19: Trade fairs, Israel, 2022

List of Figures

Figure 1: Pharmaceutical market, revenue ($B), Israel, 2014–21

Figure 2: Medical devices market, revenue ($B), Israel, 2014–21

Figure 3: Healthcare start-ups in Israel, 2022

Figure 4: Country profile, Israel, 2021

Figure 5: Pharmaceutical market, revenue ($B), Israel, 2014–21

Figure 6: Pharmaceutical market, revenue forecast ($B), Israel, 2022–27

Figure 7: Pharmaceutical exports ($B), Israel, 2014–21

Figure 8: Top export partners, Israel, 2021

Figure 9: Pharmaceutical imports ($B), Israel, 2014–21

Figure 10: Top import partners, Israel, 2021

Figure 11: Pharmaceutical supply channel, Israel, 2022

Figure 12: Medical tourism providers, Israel, 2022

Figure 13: Top medical treatments offered under medical tourism, Israel, 2022

Figure 14: Reasons to travel to Israel for medical treatment, Israel, 2022

Figure 15: Israel’s strengths in the field of personalized medicine, 2022

Figure 16: OTC medicines market ($M), major distribution channels, Israel, 2021

Figure 17: OTC market revenue ($M), Israel, 2013–21

Figure 18: OTC medicines market ($M), major categories, Israel, 2021

Figure 19: COVID-19 cases, Israel, 2020–22

Figure 20: COVID-19 deaths, Israel, 2020–22

Figure 21: COVID-19 stringency index (based on the share of people that are vaccinated), Israel, 2020–22

Figure 22: COVID-19 containment and health index, Israel, 2020–22

Figure 23: Objectives of Magen Israel, 2022

Figure 24: Probability of COVID-19 epidemic spread (R-Index), Israel, 2020-22

Figure 25: Visualization of the risk of epidemic spread based on R-Index, COVID-19, Israel, 2022

Figure 26: Traffic light plan, Israel, 2022

Figure 27: COVID-19 fiscal stimulus timeline, Israel, 2020–21

Figure 28: Collaborations of Israel Institute of Biological Research during COVID-19, Israel, 2020-22

Figure 29: High risk groups for COVID-19 , Israel, 2022

Figure 30: COVID-19 vaccine doses administration – number of vaccine doses administered, Israel, 2022

Figure 31: COVID-19 vaccine doses administered as per dose (in %), Israel, 2020-22

Figure 32: COVID-19 vaccine doses administered as per age group, Israel, 2022

Figure 33: Some of the factors for Israel’s vaccination success, Israel, 2022

Figure 34: COVID-19 clinical trials count by trial status, Israel, 2021–22

Figure 35: COVID-19 clinical trials count by trial phase, Israel, 2021–22

Figure 36: Top COVID-19 clinical trials sponsors by trial count, Israel, 2021–22

Figure 37: Medical devices market, revenue ($B), Israel, 2015–21

Figure 38: Medical devices market, revenue forecast ($B), Israel, 2022–28

Figure 39: Cardiovascular devices market, revenue ($M), Israel, 2017–27

Figure 40: Cardiovascular devices market, revenue ($M), Israel, 2017–27

Figure 41: Cardiovascular devices market, market share of major players (%), Israel, 2021

Figure 42: Hospital supplies market, revenue ($M), Israel, 2017–27

Figure 43: Hospital supplies market, market share of major players (%), Israel, 2021

Figure 44: Orthopedic devices market, revenue ($M), Israel, 2017-27

Figure 45: Orthopedic devices market, market share of major players (%), Israel, 2021

Figure 46: Neurology devices market, revenue ($M), Israel, 2017–27

Figure 47: Neurology devices market, market share of major players (%), Israel, 2021

Figure 48: General surgery devices market, revenue ($M), Israel, 2017–27

Figure 49: General surgery devices market, market share of major players (%), Israel, 2021

Figure 50: Diagnostic market, revenue ($M), Israel, 2017–2021

Figure 51: Diagnostic market, revenue ($M), Israel, 2022–27

Figure 52: Medical devices market, revenue ($B) of major companies, Israel, 2020

Figure 53: Deal value and deal count, pharmaceutical market, Israel, 2021–22

Figure 54: Deal value and deal count subtypes, pharmaceutical market, Israel, 2021–22

Figure 55: Deal value and deal count, quarterly, pharmaceutical market, Israel, 2021–22

Figure 56: Top therapy areas by deal value ($M), pharmaceutical market, Israel, 2021–22

Figure 57: Top therapy areas by deal count, pharmaceutical market, Israel, 2021–22

Figure 58: VC deals by quarter, pharmaceutical market, Israel, 2021–22 (by value and by number)

Figure 59: PE deals by quarter, pharmaceutical market, Israel, 2021–22 (by value and by number)

Figure 60: Deal value and deal count, medical devices market, Israel, 2021–22

Figure 61: Deal value and deal count subtypes, medical devices market, Israel, 2021–22

Figure 62: Deal value and deal count, quarterly, medical devices market, Israel, 2021–22

Figure 63: Top equipment sectors by deal value ($M), medical devices market, Israel, 2021–22

Figure 64: Top equipment sectors by deal count, medical devices market, Israel, 2021–22

Figure 65: M&A deals by quarter, medical devices market, Israel, 2021–22 (by value and by number)

Figure 66: VC deals by quarter, medical devices market, Israel, 2021–22 (by value and by number)

Figure 67: Fundings in subsectors of digital health, Israel, 2021

Figure 68: Deal value ($M) and deal count, Healthtech, Israel, 2021–22

Figure 69: Deal value ($M) and deal count by sector, Healthtech, Israel, 2021–22

Figure 70: Major VC deals by value and round type, Digital Health, Israel, Q2 2021

Figure 71: International collaborations of Ministry of Information and Technology, Healthtech, Israel, 2022

Figure 72: Most promising digital health firms, Israel, 2021

Figure 73: Technology in COVID-19, Israel, 2022

Figure 74: National digital program, Israel, 2021–22

Figure 75: National plan for digital health as a national growth engine, Israel, 2022

Figure 76: Overview of healthcare system, Israel, 2022

Figure 77: Groups exempted from insurance contribution, Israel, 2022

Figure 78: HMOs, Israel, 2022

Figure 79: Rights of the people insured under National Health insurance law, Israel, 2022

Figure 80: Services offered under complementary insurance plan, Israel, 2022

Figure 81: Private insurance coverage (% of the total population), Israel, 2013-18

Figure 82: OOP expenditure (% of total expenditure on health), Israel, 2013–22

Figure 83: Consumer Price Index in healthcare sector, Israel, 2016–22

Figure 84: Organization of Ministry of Health, Israel, 2022

Figure 85: Procedure of marketing authorization of new pharmaceutical drugs, Israel, 2022

Figure 86: Patent approval process, Israel, 2022

Figure 87: Members of GPPH, Israel, 2022

Figure 88: Pharmaceutical clinical trials count by trial status, Israel, 2021–22

Figure 89: Pharmaceutical clinical trials count by phase, Israel, 2021–22

Figure 90: Top five pharmaceutical clinical trials sponsors by count, Israel, 2021–22

Figure 91: Medical device clinical trials count by trial status, Israel, 2021–22

Figure 92: Medical devices clinical trials count by therapeutic areas, Israel, 2021–22

Figure 93: Medical devices clinical trials sponsors by count, Israel, 2021–22

Figure 94: Pharmaceutical clinical trials count by indication, Israel, 2021–22

Figure 95: Medical devices clinical trials count by market categories, Israel, 2021–22

Figure 96: Contents of marking template, Israel, 2022

Figure 97: Minimum labeling requirements for outer packaging, Israel, 2022

Figure 98: CCS and GPW13, Israel, 2022

Figure 99: Sustainable development goals, Israel, 2022

Figure 100: Number of hospitals, Israel, 2013–21

Figure 101: Number of diagnostic units, Israel, 2013–21

Figure 102: Hospital beds (per 1,000 population), Israel, 2013–21

Figure 103: Acute care hospital beds (per 1,000 population), Israel, 2013–21

Figure 104: Psychiatric care hospital beds (per 1,000 population), Israel, 2013–21

Figure 105: Life expectancy at birth (years), Israel, 2013–21

Figure 106: Immunization rate (%), Israel, 2013–21

Figure 107: PM2.5 (µg per m3), Israel, 2013–21

Figure 108: CO2 emissions (metric tons per capita), Israel, 2013–21

Figure 109: Physicians (per 1,000 Population), Israel, 2013–21

Figure 110: Pharmacists (per 1,000 population), Israel, 2013–21

Figure 111: Dentists (per 1,000 Population), Israel, 2013–21

Figure 112: Nurses (per 1,000 population), Israel, 2013–21

Figure 113: International collaborations of IMA, Israel, 2022

Figure 114: Major causes of mortality (per 100,000 population), Israel, 2019

Figure 115: Major causes of male mortality (per 100,000 population), Israel, 2019

Figure 116: Major causes of female mortality (per 100,000 population), Israel, 2019

Figure 117: DALYs by major disease (per 100,000 population), Israel, 2019

Figure 118: Healthcare expenditure as percentage of GDP (%), Israel, 2013–21

Figure 119: Health expenditure share (% of total health spending), Israel, 2013–21

Figure 120: Pharmaceutical spending (% of total health spending), Israel, 2013–21

Frequently Asked Questions

The Israel pharmaceutical market was valued at $2.4 billion in 2018.

 

 

 

 

The Israel medical devices market was valued at $1.6 billion in the year 2021.

The Israel medical devices market is expected to grow at a CAGR of more than 2%.

The key segments in the pharmaceutical market of Israel are generics, biologics, biosimilars, and over-the-counter (OTC).

The key players in the Israel pharmaceutical market are Sanofi, Bayer AG (Bayer), Merck & Co. (Merck), GlaxoSmithKline (GSK), Teva Pharmaceutical Industries Ltd (Teva), and  Kamada Pharmaceuticals (Kamada).

The key segments in the Israel medical devices market are Cardiovascular Devices, Hospital Supplies, Orthopedic Devices, Neurology Devices, General Surgery Devices. Cardiovascular devices has the highest revenue.

The key players in the Israel medical devices market are Abbott, GE Healthcare, Zimmer Biomet Holdings Inc (Zimmer Biomet), Coloplast A/S (Coloplast), SHL TeleMedicine Ltd (SHL), and BioView Ltd (BioView).
Buy Now

Add to Basket
$1,995

Can be used by individual purchaser only

Most Popular
$2,995

Can be shared by unlimited users within one corporate location e.g. a regional office

$3,990

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

Still undecided about purchasing this report?

Enquire Before Buying

Request a Free Sample

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
Impact of South Korea on the Pharmaceutical Industry - Thematic…
$995 | March 2023
Pharmaceuticals
New
Systemic Lupus Erythematosus and Lupus Nephritis Epidemiology Analysis and Forecast,…
$3,995 | February 2023
Pharmaceuticals
New
Ulcerative Colitis Epidemiology Analysis and Forecast, 2021-2031
$3,995 | February 2023